Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan/HCT Combination vs Candesartan Monotherapy in Hypertension
NCT00383929Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2006
- Primary completion
- Aug 2007
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of candesartan cilexetil and hydrochlorothiazide in hypertension (HTN) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in sitting Blood Pressure at 8 weeks. Started Sep 2006; status: completed.
02
Drugs
candesartan cilexetilhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00383929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383929.